Achaogen names new CMO

|About: Achaogen (AKAO)|By:, SA News Editor

Achaogen (NASDAQ:AKAO) appoints Ian Friedland, M.D., as its Chief Medical Officer. He joins the company from Cubist Pharmaceuticals (NASDAQ:CBST) where he was VP of Clinical Development. Dr. Friedland will be responsible for leading the Phase 3 clinical trial for plazomicin, the firm's lead product for serious bacterial infections due to MDR Enterobacteriaceae.